02.09.2005 19:00:00

Amgen Names Phyllis Piano Vice President, Corporate Communications and Philanthropy

Amgen (Nasdaq:AMGN) today announced the appointment ofPhyllis Piano to the position of vice president, CorporateCommunications and Philanthropy. Piano will be responsible for thecompany's strategic communications platform, including internal andexternal communications, public relations, communications issuesmanagement, master brand management, web communications and Amgen'sphilanthropy efforts.

Piano joins Amgen after serving as vice president, CorporateAffairs and Communications at Raytheon Company, a $20 billionaerospace and defense company, and a member of Raytheon's leadershipteam. Prior to joining Raytheon, she served as vice president, PublicAffairs for Cooper Industries, Inc., a manufacturer of electricalproducts, tools and hardware, and automotive products. Piano alsospent 17 years at General Electric where she progressed throughpositions of increasing responsibility in communications, includingher role as head of communications at GE Medical Systems.

About Amgen

Amgen discovers, develops and delivers innovative humantherapeutics. A biotechnology pioneer since 1980, Amgen was one of thefirst companies to realize the new science's promise by bringing safeand effective medicines from lab, to manufacturing plant, to patient.Amgen therapeutics have changed the practice of medicine, helpingmillions of people around the world in the fight against cancer,kidney disease, rheumatoid arthritis, and other serious illnesses.With a broad and deep pipeline of potential new medicines, Amgenremains committed to advancing science to dramatically improvepeople's lives. To learn more about our pioneering science and ourvital medicines, visit www.amgen.com.

EDITOR'S NOTE: An electronic version of this news release may beaccessed via our Web site at www.amgen.com. Journalists and mediarepresentatives may sign up to receive all news releaseselectronically at time of announcement by filling out a short form inthe Media section of the Web site.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Analysen zu Amgen Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Amgen Inc. 264,80 0,86% Amgen Inc.

Indizes in diesem Artikel

NASDAQ Comp. 20 053,68 0,22%
S&P 500 6 118,71 0,53%
NASDAQ 100 21 900,93 0,22%
S&P 100 2 989,86 0,60%